144 related articles for article (PubMed ID: 37234148)
1. TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefits.
Wang Y; Wang J; Fang W; Xiao X; Wang Q; Zhao J; Liu J; Yang S; Liu Y; Lai X; Song X
Front Immunol; 2023; 14():1151755. PubMed ID: 37234148
[TBL] [Abstract][Full Text] [Related]
2. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
[TBL] [Abstract][Full Text] [Related]
3. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
4. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
[TBL] [Abstract][Full Text] [Related]
5. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.
Liu Z; Lin G; Yan Z; Li L; Wu X; Shi J; He J; Zhao L; Liang H; Wang W
Front Immunol; 2022; 13():989275. PubMed ID: 36238300
[TBL] [Abstract][Full Text] [Related]
6. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
[TBL] [Abstract][Full Text] [Related]
7. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
8. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
Stenzinger A; Allen JD; Maas J; Stewart MD; Merino DM; Wempe MM; Dietel M
Genes Chromosomes Cancer; 2019 Aug; 58(8):578-588. PubMed ID: 30664300
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
14. Cancer neoantigens as potential targets for immunotherapy.
Ma W; Pham B; Li T
Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
[TBL] [Abstract][Full Text] [Related]
15. Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.
Takamatsu S; Hamanishi J; Brown JB; Yamaguchi K; Yamanoi K; Murakami K; Gotoh O; Mori S; Mandai M; Matsumura N
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35868660
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler JH; Hanks BA; Khasraw M
Clin Cancer Res; 2021 Mar; 27(5):1236-1241. PubMed ID: 33199494
[TBL] [Abstract][Full Text] [Related]
17. ecTMB: a robust method to estimate and classify tumor mutational burden.
Yao L; Fu Y; Mohiyuddin M; Lam HYK
Sci Rep; 2020 Mar; 10(1):4983. PubMed ID: 32188929
[TBL] [Abstract][Full Text] [Related]
18. Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing.
Anaya J; Sidhom JW; Cummings CA; Baras AS;
Cancer Res Commun; 2023 Mar; 3(3):501-509. PubMed ID: 36999044
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
[TBL] [Abstract][Full Text] [Related]
20. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]